GlaxoSmithKline PLC ADR (GSK)vsIntel Corporation (INTC)
GSK
GlaxoSmithKline PLC ADR
$50.41
-0.18%
HEALTHCARE · Cap: $101.38B
INTC
Intel Corporation
$124.92
+13.96%
TECHNOLOGY · Cap: $627.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Intel Corporation generates 64% more annual revenue ($53.76B vs $32.78B). GSK leads profitability with a 17.8% profit margin vs -5.9%. GSK appears more attractively valued with a PEG of 0.50. GSK earns a higher WallStSmart Score of 66/100 (B-).
GSK
Strong Buy66
out of 100
Grade: B-
INTC
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-3.1%
Fair Value
$56.71
Current Price
$50.41
$6.30 premium
Margin of Safety
-28.5%
Fair Value
$35.50
Current Price
$124.92
$89.42 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 36.3%
Large-cap with strong market position
Attractively priced relative to earnings
Mega-cap, among the largest globally
Areas to Watch
1.5% revenue growth
Elevated debt levels
Distress zone — elevated risk
Distress zone — elevated risk
ROE of -2.9% — below average capital efficiency
Earnings declined 71.7%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 36.3%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : INTC
The strongest argument for INTC centers on Market Cap. PEG of 1.36 suggests the stock is reasonably priced for its growth.
Bear Case : GSK
The primary concerns for GSK are Revenue Growth, Debt/Equity, Altman Z-Score.
Bear Case : INTC
The primary concerns for INTC are Altman Z-Score, Return on Equity, EPS Growth.
Key Dynamics to Monitor
GSK profiles as a value stock while INTC is a turnaround play — different risk/reward profiles.
INTC carries more volatility with a beta of 2.19 — expect wider price swings.
INTC is growing revenue faster at 7.2% — sustainability is the question.
GSK generates stronger free cash flow (698M), providing more financial flexibility.
Bottom Line
GSK scores higher overall (66/100 vs 33/100), backed by strong 17.8% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Intel Corporation
TECHNOLOGY · SEMICONDUCTORS · USA
Intel Corporation is an American multinational corporation and technology company headquartered in Santa Clara, California, in Silicon Valley. It is the world's largest semiconductor chip manufacturer by revenue, and is the developer of the x86 series of microprocessors, the processors found in most personal computers (PCs).
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?